Cue Biopharma (CUE)

Executive Summary

Cue Biopharma is a clinical-stage biotechnology company advancing its proprietary Immuno-STAT™ platform to selectively modulate T cells for the treatment of cancer and autoimmune diseases. The platform aims to restore immune balance by precisely targeting disease-relevant T cells, offering a potential alternative to broad immunosuppression or activation. The company's lead program, CUE-101, is being evaluated in Phase 2 trials for HPV-positive oropharyngeal squamous cell carcinoma (OPSCC) as a monotherapy and in combination with pembrolizumab for locally advanced head and neck squamous cell carcinoma (HNSCC). Additionally, CUE-102 is in Phase 1 testing for recurrent glioblastoma, following a completed Phase 1 trial in colorectal cancer. Cue Biopharma's approach has the potential to address significant unmet needs in oncology and autoimmune indications by harnessing the immune system with high specificity.

Upcoming Catalysts (preview)

• H1 2027Phase 2 data readout for CUE-101 in OPSCC40% success
• H2 2026Phase 1 interim data for CUE-102 in glioblastoma35% success
• TBDPotential partnership or licensing deal for Immuno-STAT platform30% success